Back to search
FDAFDA · Food and drugs·Recall number D-0673-2026

Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01

Published July 15, 2026 · Recall initiated: June 24, 2026

Summary

FDA records drug Class II recall D-0673-2026, published July 15, 2026 and initiated June 24, 2026. Recalling firm: Reliance Life Sciences Private Limited; Status: Ongoing; Reported quantity: 11,400 vials; Lot: Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Sterility Assurance

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Reliance Life Sciences Private Limited
Distributor
Nationwide in the USA
Lot
Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01 recalled?

Yes. FDA published recall D-0673-2026 on July 15, 2026. Reported hazard: Lack of Sterility Assurance

What should I do if I have this product?

Voluntary: Firm initiated · Letter